petros pharmaceuticals shares declined 9 to 324 friday after the company announced a 15 million private placement petros which focuses on mens health issues including erectile dysfunction and endothelial dysfunction said thursday that the agreement includes preferred stock and warrants to buy up to 67 million common shares petros expects the funding combined with cash on its balance sheet to provide a strong cash position that will fund its initiatives through the end of 2024